The National Healthcare Quality and Disparities Reports have moved to the new AHRQ Data Tools site. After June 30, 2022, this web page will no longer be available.

WisconsinPrevention Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Prevention are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Estimate Benchmark Distance to Benchmark
Adults ages 18-64 at high risk (e.g., COPD) who ever received pneumococcal vaccination 47.9 44.8 Achieved: 7% better
Home health patients who had influenza vaccination during flu season 97.8 94.1 Achieved: 4% better
Adults age 65 and over who ever received pneumococcal vaccination 79.7 78.7 Achieved: 1% better
Adults who received a blood cholesterol measurement in the last 5 years 82.9 82.3 Achieved: 1% better
Home health patients who had pneumococcal polysaccharide vaccination 91.7 91.0 Achieved: 1% better
Women ages 21-65 who received a Pap smear in the last 3 years 83.7 84.2 0.6%
Long-stay nursing home residents who were assessed for pneumococcal vaccination 96.2 97.0 0.9%
Long-stay nursing home patients who were assessed and appropriately given the seasonal influenza vaccine 92.6 93.9 1.4%
Adolescents ages 16-17 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 94.4 95.9 1.6%
Short-stay nursing home residents who were assessed for pneumococcal vaccination 89.4 91.4 2.1%
Short-stay nursing home patients who had flu vaccination appropriately given 89.8 92.2 2.6%
Women ages 50-74 who received a mammogram in the last 2 years 80.3 84.7 5.2%
Children ages 19-35 months who received 3 or more doses of hepatitis B vaccine 90.3 96.4 6.3%
Children ages 19-35 months who received 1 or more doses of measles-mumps-rubella vaccine 89.9 96.4 6.7%
Children ages 19-35 months who received 3 or more doses of polio vaccine 89.7 97.3 7.8%
Adolescents ages 16-17 who received 1 or more doses of meningococcal conjugate vaccine 88.3 96.2 8.2%
Adolescents ages 13-15 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 87.4 95.2 8.2%
Children ages 19-35 months who received 1 or more doses of varicella vaccine 87.1 95.7 9.0%
Measures That Are Close to Benchmark
Measure Estimate Benchmark Distance to Benchmark
Children ages 19-35 months who received 4 or more doses of diphtheria-tetanus-pertussis vaccine 81.1 90.6 10.5%
Adults ages 18-64 at high risk (e.g., COPD) who received an influenza vaccination in the last flu season 41.4 47.8 13.4%
Adolescents ages 13-15 who received 1 or more doses of meningococcal conjugate vaccine 80.7 95.4 15.4%
Breast cancer diagnosed at advanced stage (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and over 91.7 73.8 24.3%
Adults age 65 and over who received an influenza vaccination in the last flu season 53.2 70.3 24.3%
Cervical cancer diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over 9.7 7.7 25.6%
Colorectal cancer diagnosed at advanced stage (tumors diagnosed at regional or distant stage) per 100,000 population age 50 and over 64.8 48.6 33.3%
Measures With No Available Benchmark Information
Measure Estimate Benchmark Distance to Benchmark
Adolescents females ages 16-17 who received 3 or more doses human papillomavirus vaccine